Drug & intervention

glucagon

RxCUI 4832

Clinical trials40
Recruiting0
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Glucagon

Glucagon is a peptide hormone, produced by alpha cells of the pancreas. It raises the concentration of glucose and fatty acids in the bloodstream and is considered to be the main catabolic hormone of the body. It is also used as a medication to treat a number of health conditions. Its effect is opposite to that of insulin, which lowers extracellular glucose. It is produced from proglucagon, encoded by the GCG gene. The pancreas releases glucagon when the amount of glucose in the bloodstream is too low. Glucagon causes the liver to engage in glycogenolysis: converting stored glycogen into glucose, which is released into the bloodstream. High blood-glucose levels, on the other hand, stimulate the release of insulin. Insulin allows glucose to be taken up and used by insulin-dependent tissues. Thus, glucagon and insulin are part of a feedback system that keeps blood glucose levels stable. Glucagon increases energy expenditure and is elevated under conditions of stress. Glucagon belongs to the secretin family of hormones.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
Human Models of Selective Insulin Resistance: Pancreatic ClampNCT06558422 · 2027-01-01
NOT_YET_RECRUITING
Studies of Insulin and Glucagon Action in the LiverNCT07300982 · 2026-10-01
NOT_YET_RECRUITING
Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese AdolescentsNCT06588504 · 2024-09-10
COMPLETED
Dexamethasone/Pancreatic Clamp P&FNCT06126354 · 2024-07-01
WITHDRAWN
Glucagon Enhanced Insulin Absorption in Diabetes Mellitus Type 1NCT05960565 · 2023-12-22
TERMINATED
Pancreatic Clamp in NAFLDNCT05724134 · 2023-08-29
COMPLETED
Dual-Hormone Closed-Loop Glucose Control in Adolescents With Type 1 DiabetesNCT04949867 · 2021-05-20
COMPLETED
A Trial to Investigate Hyperglycemic and Hypoglycemic Excursions in Subjects With Type 1 DiabetesNCT04712266 · 2020-09-15
COMPLETED
Metabolic Adaptation to High-frequent Hypoglycaemia in Type 1 DiabetesNCT05095259 · 2019-12-16
UNKNOWN
Glucagon Regulation of Glucose MetabolismNCT04347252 · 2019-09-24
COMPLETED
Dual-hormone Closed-loop Glucose Control in Type 1 DiabetesNCT04053712 · 2019-07-16
COMPLETED
Liver Glycogen and Hypoglycemia in HumansNCT03241706 · 2018-08-02
ACTIVE_NOT_RECRUITING
Hepatic Metabolic Changes in Response to Glucagon InfusionNCT03526445 · 2018-05-01
COMPLETED
Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory ResponsesNCT03490942 · 2018-03-15
TERMINATED
First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.NCT03444467 · 2018-02-05
COMPLETED
Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 DiabetesNCT02490098 · 2018-01-01
WITHDRAWN
Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese SubjectsNCT03139305 · 2017-10-24
ACTIVE_NOT_RECRUITING
Efficacy of Glucagon In the Prevention of Hypoglycemia During Mild ExerciseNCT03217175 · 2017-08-18
TERMINATED
Intranasal Glucagon and Energy BalanceNCT03650582 · 2017-06-06
UNKNOWN
Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D PatientsNCT03091673 · 2017-03-27
COMPLETED
A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes MellitusNCT02910518 · 2017-02-17
COMPLETED
To Determine Tolerability to Glucagon Infusion in Obese SubjectsNCT02817659 · 2016-11-01
ACTIVE_NOT_RECRUITING
Feasibility Trial Testing the Bionic Pancreas With ZP4207NCT02971228 · 2016-11-01
COMPLETED
Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation - Part 2NCT02798250 · 2016-06-01
COMPLETED
Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of GlucagonNCT02516150 · 2016-03-01
COMPLETED
Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop OperationNCT02626936 · 2016-01-01
COMPLETED
Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 DiabetesNCT02232971 · 2014-09-01
UNKNOWN
Effects of Glucagon Administration on Energy ExpenditureNCT02237053 · 2014-09-01
COMPLETED
Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon DosagesNCT01916265 · 2013-08-01
COMPLETED
Efficacy of Small Subcutaneous Glucagon Dose to Treat Hypoglycemia in Adults With Type 1 DiabetesNCT01828125 · 2013-04-01
WITHDRAWN
Study of LY2409021 in Participants With Type 1 DiabetesNCT01640834 · 2012-07-01
COMPLETED
Physiologic Response to Glucagon at Varying Insulin LevelsNCT01483651 · 2011-11-01
COMPLETED
Effect of LY2189265 on Insulin Secretion in Response to Intravenous GlucoseNCT01300260 · 2011-02-01
COMPLETED
Safety Study of Repeated Doses of Glucagon on Animal Starch in the LiverNCT01986231 · 2011-01-01
COMPLETED
Acute Regulation of Intestinal and Hepatic Lipoprotein Production by GlucagonNCT01155206 · 2009-06-01
COMPLETED
To Evaluate the Response to Glucagon During HypoglycemiaNCT00817271 · 2009-02-01
COMPLETED
A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal SubjectsNCT00823940 · 2009-01-13
COMPLETED
Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin AloneNCT00797823 · 2008-11-01
COMPLETED
Glucagon in the Treatment of Hypoglycemia in Newborn Infants of Diabetic MothersNCT00434772 · 2007-12-01
COMPLETED
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 15 Weeks in Adolescents and Adults With Type 1 DiabetesNCT02846857
WITHDRAWN

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.